Table 2.
Summary of the most relevant clinical trials with novel proteasome inhibitors in monotherapy in relapsed/refractory MM
| Drug | Trial | Phase | n | Prior lines |
ORR (≥ PR) |
PFS (months) |
Reference |
|---|---|---|---|---|---|---|---|
|
Carfilzomib (PR-171) |
PX–171–001 | 1 | 10 MM | - | 10% | - | O’Connor. CCR 2009[152] |
| PX–171–002 | 1 | 28 | - | 19% | - | Alsina. CCR 2012[153] |
|
| PX-171- 003A0 |
2 | 46 | 5 (2–16) | 17% | 3.5 | Jagannath. Clin Lymph Myeloma 2012[154] |
|
| PX–171– 003A1 |
2 | 266 | 5 (1–20) | 24% | 3.7 | Siegel. Blood 2012[155] |
|
| PX–171–004 | 2 | 129 Btz naïve patients |
2 (1–4) | C-1: 42% C-2: 52% |
C-1: 8.2 C-2: NR |
Vij Blood 2012[83] | |
| 35 Btz treated patients |
3 (1–13) | 17% | 4.6 | Vij BJH 2012[85] | |||
| PX-171–005 | 2 | 50 (Renal impairment) |
5 (1–15) | 26% | - | Badros. Leukemia 2013[102] |
|
|
Ixazomib (MLN-9708) |
C16004 | 1 | 60 | 6 (2–18) | 15% | - | Kumar. ASCO 2013[106] |
| C16003 | 1 | 57 | 4 (1–28) | 13% | - | Lonial. ASCO 2012[107] |
|
|
Marizomib (NPI-0052) |
NPI-0052–101 NPI-0052–102 |
1 | 34 | 6 | 14% | - | Richardson. ASH 2011[110] |
NR: Not reached